Kexing Biopharm Co., Ltd. (SHA:688136)
China · Delayed Price · Currency is CNY 29.54
+2.37 (8.72%)
Mar 30, 2026, 3:00 PM CST
Kexing Biopharm Market Cap
Kexing Biopharm has a market cap or net worth of 5.38 billion as of March 30, 2026. Its market cap has increased by 32.83% in one year.
Market Cap
5.38B
Enterprise Value
6.17B
Revenue
1.54B
Ranking
n/a
PE Ratio
33.54
Stock Price
29.54
Market Cap Chart
Since December 14, 2020, Kexing Biopharm's market cap has decreased from 8.15B to 5.38B, a decrease of -33.95%. That is a compound annual growth rate of -7.55%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 27, 2026 | 5.38B | -14.21% |
| Dec 31, 2025 | 6.27B | 45.13% |
| Dec 31, 2024 | 4.32B | 7.17% |
| Dec 29, 2023 | 4.03B | -5.31% |
| Dec 30, 2022 | 4.26B | -24.16% |
| Dec 31, 2021 | 5.62B | -30.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 14, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GemPharmatech | 6.00B |
| Lifecome Biochemistry | 5.92B |
| R&G PharmaStudies | 5.91B |
| Shanghai OPM Biosciences | 5.80B |
| Shouyao Holdings (Beijing) Co., LTD. | 5.77B |
| Novogene | 5.59B |
| Beijing Konruns Pharmaceutical | 5.57B |
| ChemPartner PharmaTech | 5.11B |